| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8474358 | Journal of Molecular and Cellular Cardiology | 2015 | 8 Pages |
Abstract
In conclusion, PCSK9 activity can be modulated by splice-switching through an RNA therapeutic approach. The tuning of the natural active to non-active isoforms represents a physiological way of regulating the cholesterol metabolism, by controlling the amount of LDL receptor available and the rate of LDL-cholesterol clearance.
Keywords
RIPAphosphorodiamidate morpholinoRNA therapeuticsSplice-switching oligonucleotidestris/borate/EDTAPCSK9SREBPsHprtTBSTTBECTRLNALDL-CLDLRRP-HPLCPBSTPBSCRISPRFBSPMOSSOLPDsSmall interfering RNAsiRNAradio-immunoprecipitation assayEDTAEthylenediaminetetraacetic acidLocked Nucleic Acidclustered regularly interspaced short palindromic repeatsstandard error of the meanfetal bovine serumPhosphate-buffered salineSEMHypercholesterolemiahypoxanthine-guanine phosphoribosyltransferaseProprotein convertase subtilisin/kexin type 9Gene therapyreverse-phase high-performance liquid chromatographyLow-density lipoprotein cholesterollipoprotein deficient serumControlLow-density lipoprotein receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Cristina S.J. Rocha, Oscar P.B. Wiklander, Lilian Larsson, Pedro M.D. Moreno, Paolo Parini, Karin E. Lundin, C.I. Edvard Smith,